Roche Pharmaceutical Development and Sales Overview slide image

Roche Pharmaceutical Development and Sales Overview

Roche Giredestrant: Early data support continued development in ER+ BC Ph III (persevERA) interim results in 1L ER+ BC expected for 2024 Ph II (acelERA) results in 2/3L ER+/HER- BC Ph II (coopERA) results in neoadjuvant ER+/HER- BC PFS-INV: ESR1m subgroup 100+ 90- 80- 70- PFS-INV, % 60- 50 40- 30- 20- 10- 0- 0 2 4 6 8 10 12 14 Months No. at risk giredestrant 51 36 26 12 9 4 PCET 39 20 9 1 congress PARIS 2022 ESMO HR (95% CI) p-value (log-rank) mPFS, months giredestrant (n = 51) PCET (n = 39) 0.60 (0.35, 1.03) 0.0610 5.3 3.5 Ki67 response at wk 2 and at surgery Relative reduction in Ki67% from baseline OHNWAG Baseline to week 2 Giredestrant (n=107) -75% Anastrazole (n=94) -67% Baseline to surgery G+P (n = 93) -81% A+P (n=91) -74% 2022 ASCO ANNUAL MEETING 。%% 0.00 -0.25- -0.50- -0.75- -1.00- • • . PFS benefit was more pronounced in patients with ESR1 mutations (HR of 0.81 in all-comers vs HR of 0.60 in patients with ESR1 mutations) In 2L/3L setting patients have received multiple cycles of ET The activity observed in patients whose tumours still depend on estrogen receptor activity for viability is encouraging for earlier lines, where nearly all ER+ tumours are dependent on ER activity . G+P, Giredestrant + Palbociclib; A+P, Anastrozole + Palbociclib First randomized study to show superior activity of an oral SERD (giredestrant) over an aromatase inhibitor (anastrozole) in ER+/HER2- eBC Final analysis confirmed greater suppression of Ki67 and rates of complete cell cycle arrest with giredestrant vs. anastrazole at time of surgery Ki67 is a biomarker of proliferation associated with improved long-term efficacy outcomes in early stage disease Safety data consistent with known safety profile Fasching P et al., ASCO 2022; Martin M et al., ESMO 2022; Clinical cutoff: 18 Feb 2022; median follow-up 7.89 months; SERD-Selective estrogen receptor degrader; BC-Breast cancer; ER=estrogen receptor; ESR1-estrogen receptor 1; ET-estrogen therapy; PFS-INV-progression-free survival by investigator assessment; HR-hazard ratio; PCET=physician's choice of endocrine therapy; HER2-Human epidermal growth factor receptor 2 22 21
View entire presentation